Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

NCT06400485 is registered in ClinicalTrials.gov with Multitude Therapeutics Inc. as lead sponsor.

NCT NCT06400485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Lead sponsor
Multitude Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 18, 2024
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors